Wyss is the ninja institute: it’s everywhere and anywhere, but only other ninjas can detect it. Of course it’s deeply involved with Covid and the jabs too. This piece of their work is over a decade old, but you can easily see how it plays out in the 2020’s.

Wyss Institute Develops New Nanodevice Manufacturing Strategy Using Self-Assembling DNA “Building Blocks”

May 30, 2012

Novel technology could enable new tools for delivering drugs directly to disease sites in the body

Researchers at the Wyss Institute have developed a method for building complex nanostructures out of short synthetic strands of DNA. Called single-stranded tiles (SSTs), these interlocking DNA “building blocks,” akin to Legos®, can be programmed to assemble themselves into precisely designed shapes, such as letters and emoticons. Further development of the technology could enable the creation of new nanoscale devices, such as those that deliver drugs directly to disease sites.

The technology, which is described in today’s online issue of Nature, was developed by a research team led by Wyss core faculty member Peng Yin, Ph.D., who is also an Assistant Professor of Systems Biology at Harvard Medical School. Other team members included Wyss Postdoctoral Fellow Bryan Wei, Ph.D., and graduate student Mingjie Dai.

DNA is best known as a keeper of genetic information. But in an emerging field of science known as DNA nanotechnology, it is being explored for use as a material with which to build tiny, programmable structures for diverse applications. To date, most research has focused on the use of a single long biological strand of DNA, which acts as a backbone along which smaller strands bind to its many different segments, to create shapes. This method, called DNA origami, is also being pursued at the Wyss Institute under the leadership of Core Faculty member William Shih, Ph.D. Shih is also an Associate Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Department of Cancer Biology at the Dana-Farber Cancer Institute.

Examples of self-assembled DNA building blocks
Wyss researchers have built numerals, letters, and a number of other structures using short strands of DNA as building blocks.

In focusing on the use of short strands of synthetic DNA and avoiding the long scaffold strand, Yin’s team developed an alternative building method. Each SST is a single, short strand of DNA. One tile will interlock with another tile, if it has a complementary sequence of DNA. If there are no complementary matches, the blocks do not connect. In this way, a collection of tiles can assemble itself into specific, predetermined shapes through a series of interlocking local connections.

In demonstrating the method, the researchers created just over one hundred different designs, including Chinese characters, numbers, and fonts, using hundreds of tiles for a single structure of 100 nanometers (billionths of a meter) in size. The approach is simple, robust, and versatile.

As synthetically based materials, the SSTs could have some important applications in medicine. SSTs could organize themselves into drug-delivery machines that maintain their structural integrity until they reach specific cell targets, and because they are synthetic, can be made highly biocompatible.

“Use of DNA nanotechnology to create programmable nanodevices is an important focus at the Wyss Institute, because we believe so strongly in its potential to produce a paradigm-shifting approach to development of new diagnostics and therapeutics,” said Wyss Founding Director, Donald Ingber, M.D., Ph.D.

The research was supported by the Office of Naval Research, the National Science Foundation, the National Institutes of Health, and the Wyss Institute at Harvard University.

Source – Wyss Institute

UPDATE DECEMBER 2, 2021

WYSS Inst. presents: Xenobots 3.0: The New Living Robots That Can Reproduce
live webinar on December 1, 2021

Also read:

WE WRITE NEW DNA USING RNA ONLY – STAR SCIENTIST FINANCED BY EPSTEIN, DARPA AND SCHWAB’S WYSS INST.

To find out how Wyss relates to Klaus Schwab, read:

PULITZER-WORTHY! KLAUS SCHWAB’S NAZI ROOTS FINALLY TRACED!

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
We hardly made it before, but this summer something’s going on, our audience stats show bizarre patterns, we’re severely under estimates and the last savings are gone. We’re not your responsibility, but if you find enough benefits in this work…
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

We gave up on our profit shares from masks, if you want to help us, please use the donation button!
We think frequent mask use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness.
Get it here!

If you’re familiar with our reports, George Church is no stranger to you either. He’s a founder figure for the Human Genome Project, CRISPR and The BRAIN Initiative. But he’s totally not getting the deserved attention, seeing that he’s just turned our world upside down. Not by himself, of course.

Remember when Fauci and Big Tech joined efforts to keep us in the dark in regards to the mRNA impact on our genetics and DNA?


We’ve shown that there’s an entire new field of science that does just that: argues what Fauci said using RNA to reprogram DNA.
But we’ve just reached a deeper level of the rabbit hole that we didn’t even know it’s there already. It’s been there for a while. As in 2020 minus “three years of stealth operations”. If you read carefully below, it will all make much more sense.

George M. Church biography as per Harvard website

Professor at Harvard & MIT, co-author of 580 papers, 143 patent publications & the book “Regenesis”; developed methods used for the first genome sequence (1994) & million-fold cost reductions since (via fluor-NGS & nanopores), plus barcoding, DNA assembly from chips, genome editing, writing & recoding; co-initiated BRAIN Initiative (2011) & Genome Projects (GP-Read-1984, GP-Write-2016, PGP-2005:world’s open-access personal precision medicine datasets); machine learning for protein engineering, tissue reprogramming, organoids, xeno-transplantation, in situ 3D DNA, RNA, protein imaging.

SEE MORE

George Church is Professor of Genetics at Harvard Medical School and Director of  PersonalGenomes.org, which provides the world’s only open-access information on human Genomic, Environmental & Trait data (GET). His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing & barcoding. These led to the first genome sequence (pathogen, Helicobacter pylori) in  1994 . His innovations have contributed to nearly all “next generation” DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This plus his lab’s work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics ( Knome/PierianDxAlacrisAbVitro/JunoGenosVeritas Genetics ) & synthetic biology / therapeutics ( JouleGen9EditasEgenesisenEvolvWarpDrive ). He has also pioneered new privacybiosafetyELSIenvironmental & biosecurity policies. He is director of an IARPA BRAIN Project and NIH Center for Excellence in Genomic Science. His honors include election to NAS & NAE & Franklin Bower Laureate for Achievement in Science. He has coauthored 537 papers156 patent publications & one book (Regenesis).

THIS IS BGI
THIS IS ILLUMINA

PhD students from (* = main training programs for our group):
Harvard University: Biophysics* , BBS* , MCB , ChemBio* , SystemsBio* , Virology
MIT: HST*ChemistryEE/CSPhysicsMath.
Boston Universty: BioinformaticsBiomedical Engineering
Cambridge University, UK: Genetics

PublicationsCVs-resumesLab members , Co-author netELSI
Technology transfer & Commercial Scientific Advisory Roles
Personal info — News — Awards — Grant proposals
Director of Research Centers: DOE-Biotechnologies (1987), NIH-CEGS (2004), PGP (2005), Lipper Center for Computational Genetics (1998), Wyss Inst. Synthetic Biology (2009). Other centers: Regenesis Inst. (2017), SIAT Genome Engineering (2019), Space Genetics (2016), WICGR, Broad Inst. (1990), MIT Media Lab (2014)

Updated: 15-Jan-02021

The BRAIN initiative[edit]

He was part of a team of six[80] who, in a 2012 scientific commentary, proposed a Brain Activity Map, later named BRAIN Initiative (Brain Research through Advancing Innovative Neurotechnologies).[81] They outlined specific experimental techniques that might be used to achieve what they termed a “functional connectome“, as well as new technologies that will have to be developed in the course of the project,[80] including wireless, minimally invasive methods to detect and manipulate neuronal activity, either utilizing microelectronics or synthetic biology. In one such proposed method, enzymatically produced DNA would serve as a “ticker tape record” of neuronal activity.Wikipedia

SEE THE NAZI ORIGINS OF WYSS HERE

Wyss Institute Will Lead IARPA-Funded Brain Mapping Consortium

January 26, 2016

(BOSTON) — The Wyss Institute for Biologically Inspired Engineering at Harvard University today announced a cross-institutional consortium to map the brain’s neural circuits with unprecedented fidelity. The consortium is made possible by a $21 million contract from the Intelligence Advanced Research Projects Activity (IARPA) and aims to discover the brain’s learning rules and synaptic ‘circuit design’, further helping to advance neurally-derived machine learning algorithms.

The consortium will leverage the Wyss Institute’s FISSEQ (fluorescent in-situ sequencing) method to push forward neuronal connectomics, the science of identifying the neuronal cells that work together to bring about specific brain functions. FISSEQ was developed in 2014 by the Wyss Core Faculty member George Church and colleagues and, unlike traditional sequencing technologies, it provides a method to pinpoint the precise locations of specific RNA molecules in intact tissue. The consortium will harness this FISSEQ capability to accurately trace the complete set of neuronal cells and their connecting processes in intact brain tissue over long distances, which is currently difficult to do with other methods.

Awarded a competitive IARPA MICrONS contract, the consortium will further the overall goals of President Obama’s BRAIN initiative, which aims to improve the understanding of the human mind and uncover new ways to treat neuropathological disorders like Alzheimer’s disease, schizophrenia, autism and epilepsy. The consortium’s work will fundamentally innovate the technological framework used to decipher the principal circuits neurons use to communicate and fulfill specific brain functions. The learnings can be applied to enhance artificial intelligence in different areas of machine learning such as fraud detection, pattern and image recognition, and self-driving car decision making.

See how the Wyss-developed FISSEQ technology is able to capture the location of individual RNA molecules within cells, which will allow the reconstruction of neuronal networks in the 3-dimensional space of intact brain tissue. Credit: Wyss Institute at Harvard University

“Historically, the mapping of neuronal paths and circuits in the brain has required brain tissue to be sectioned and visualized by electron microscopy. Complete neurons and circuits are then reconstructed by aligning the individual electron microsope images, this process is costly and inaccurate due to use of only one color (grey),” said Church, who is the Principal Investigator for the IARPA MICrONs consortium. “We are taking an entirely new approach to neuronal connectomics_immensely colorful barcodes_that should overcome this obstacle; and by integrating molecular and physiological information we are looking to render a high-definition map of neuronal circuits dedicated first to specific sensations, and in the future to behaviors and cognitive tasks.”

Church is Professor of Genetics at Harvard Medical School, and Professor of Health Sciences and Technology at Harvard and MIT.

To map neural connections, the consortium will genetically engineer mice so that each neuron is barcoded throughout its entire structure with a unique RNA sequence, a technique called BOINC (Barcoding of Individual Neuronal Connections) developed by Anthony Zador at Cold Spring Harbor Laboratory. Thus a complete map representing the precise location, shape and connections of all neurons can be generated.

The key to visualizing this complex map will be FISSEQ, which is able to sequence the total complement of barcodes and pinpoint their exact locations using a super-resolution microscope. Importantly, since FISSEQ analysis can be applied to intact brain tissue, the error-prone brain-sectioning procedure that is part of common mapping studies can be avoided and long neuronal processes can be more accurately traced in larger numbers and at a faster pace.

In addition, the scientists will provide the barcoded mice with a sensory stimulus, such as a flash of light, to highlight and glean the circuits corresponding to that stimulus within the much more complex neuronal map. An improved understanding of how neuronal circuits are composed and how they function over longer distances will ultimately allow the team to build new models for machine learning.

The multi-disciplinary consortium spans 6 institutions. In addition to Church, the Wyss Institute’s effort will be led by Samuel Inverso, Ph.D., who is a Staff Software Engineer and Co-investigator of the project. Complementing the Wyss team, are co-Principal Investigators Anthony Zador, Ph.D., Alexei Koulakov, Ph.D., and Jay Lee, Ph.D., at Cold Spring Harbor Laboratory. Adam Marblestone, Ph.D., and Liam Paninski, Ph.D. are co-Investigator at MIT and co-Principal Investigator at Columbia University, respectively. The Harvard-led consortium is partnering with another MICrONS team led by Tai Sing Lee, Ph.D. of Carnegie Mellon University as Principal investigator under a separate multi-million contract, with Sandra Kuhlman, Ph.D. of Carnegie Mellon University and Alan Yuille, Ph.D. of Johns Hopkins University as co-Principal investigators, to develop computational models of the neural circuits and a new generation of machine learning algorithms by studying the behaviors of a large population of neurons in behaving animals, as well as the circuitry of the these neurons revealed by the innovative methods developed by the consortium.

“It is very exciting to see how technology developed at the Wyss Institute is now becoming instrumental in showing how specific brain functions are wired into the neuronal architecture. The methodology implemented by this research can change the trajectory of brain mapping world wide,” said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. – WYSS Institute

IARPA is CIA’s DARPA.
DARPA IS RAN BY PENTAGON AND IARPA BY CIA.
IARPA IS EVEN MORE SECRETIVE, DARING AND SOCIOPATHIC.

Machine Intelligence from Cortical Networks (MICrONS)

Intelligence Advanced Research Projects Activity (IARPA)

Brain Research through Advancing Innovative Neurotechnologies. (BRAIN)

Background
The science behind Obama’s BRAIN project. (BrainFacts, 15Apr-2013 | Jean-François Gariépy)
Wyss Institute Will Lead IARPA-Funded Brain Mapping Consortium (Wyss, 26-Jan-2016 |)
Project Aims to Reverse-engineer Brain Algorithms, Make Computers Learn Like Humans (Scientific Computing, 4-Feb-2016 | Byron Spice)
The U.S. Government Launches a $100-Million “Apollo Project of the Brain” (Scientific American, 8-Mar-2016 | Jordana Cepelewicz)

Grant Proposal
Tasks 2 & 3 PDF Harvard, Wyss, CSHL, MIT.
Task 1. CMU.


Molecular TickertapeRelated Projects:

Full Rosetta brains in situ
A. Activity (MICrONS = Ca imaging) (Alternative=Tickertape, see figure to right)
B. Behavior (MICrONS & Alt = traditional video)
C. Connectome (MICrONS & Alt = BOINC via Cas9-barcode)
D. Developmental Lineage (via Cas9-barcode)
E. Expression (RNA & Protein via FISSEQ)

Building brain components, circuits and organoids.
Busskamp V, Lewis NE, Guye P, Ng AHM, Shipman S, Byrne SS, Sanjana NE, Li Y, Weiss R, Church GM (2014)
Rapid neurogenesis through transcriptional activation in human stem cells. Molecular Systems Biology MSB 10:760:1-21

SOURCE

Flagship Pioneering’s Scientists Invent a New Category of Genome Engineering Technology: Gene Writing

Tessera Therapeutics emerges from three years of stealth operations to pioneer Gene Writing™ as a new genome engineering technology and category of genetic medicine

(PRNewsfoto/Flagship Pioneering)

NEWS PROVIDED BY Flagship Pioneering 

Jul 07, 2020, 08:00 ET


CAMBRIDGE, Mass., July 7, 2020 /PRNewswire/ — Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes therapeutic messages into the genome to treat diseases at their source.

Tessera’s Gene Writing platform is a potentially revolutionary breakthrough for genetic medicine that addresses key limitations of gene therapy and gene editing. Gene Writing technology can alter the genome by efficiently inserting genes and exons (parts of genes), introducing small insertions and deletions, or changing single or multiple DNA base pairs. The technology could enable cures for diseases that arise from errors in the genome, including monogenic disorders. It could also allow precise gene regulation in other diseases such as neurodegenerative diseases, autoimmune disorders, and metabolic diseases.

“While profound advancements in genetic medicine over the last two decades had therapeutic promise for many previously untreatable diseases, the intrinsic properties of existing gene therapy and editing have significant shortcomings that limit their benefits to patients,” says Noubar Afeyan, Ph.D., founder and CEO of Flagship Pioneering and Chairman of Tessera Therapeutics. “Our scientists have invented a new technology, called Gene Writing, that has the ability to write therapeutic messages into the genomes of somatic cells. We created Tessera to pioneer its applications for medicine. However, the breakthrough is broad and could be applied to many different genomes from humans to plants to microorganisms.”

A New Era of Genetic Medicine

Geoffrey von Maltzahn, Ph.D., an MIT-trained biological engineer; Jacob Rubens, Ph.D., an MIT-trained synthetic biologist; and other scientists at Flagship Labs, the enterprise’s innovation foundry, co-founded Tessera in 2018 to create a platform that could design, make, and launch Gene Writing medicines. A General Partner at Flagship Pioneering, von Maltzahn has co-founded numerous biotechnology companies, including Sana Biotechnology, Indigo Agriculture, Kaleido Biosciences, Seres Therapeutics, and Axcella Health.

“DNA codes for life. But sometimes our DNA is written improperly, driving an enormous variety of diseases,” says von Maltzahn, Tessera’s Chief Executive Officer. “We started Tessera Therapeutics with a simple question: ‘What if Nature evolved a better solution than CRISPR for inserting curative therapeutic messages into the genome?’ It turns out that engineered and synthetic mobile genetic elements offer the potential to go beyond the limitations of gene editing technologies and allow Gene Writing. Our outstanding team of scientists is focused on bringing the vast promise of this new technology category to patients.”

Mobile genetic elements, the inspiration for Gene Writing, are evolution’s greatest genomic architect. The first mobile genetic element was discovered by Barbara McClintock, who won the 1983 Nobel Prize for revealing the mobile nature of genes. Mobile genetic elements code for the machinery to move or copy themselves into a new location in the genome, and they have been selected over billions of years to autonomously and efficiently “write” their DNA into new genomic sites. Today, mobile genetic elements are among the most abundant and ubiquitous genes in nature.

Over the past two years, Tessera has been mining genomes to discover novel mobile genetic elements and engineering them to create Gene Writing technology.

Tessera’s Gene Writers write therapeutic messages into the genome using RNA or DNA templates. RNA-based Gene Writing uses an RNA template and Gene Writer protein to either write a new gene into the genome or guide the rewriting of a pre-existing genomic sequence to make a small substitution, insertion, or deletion. DNA-based Gene Writing uses a DNA template to write a new gene into the genome.

By harnessing the biology of mobile genetic elements, Gene Writing holds the potential to overcome the limitations of current genetic medicine approaches by:

  • Efficiently writing small and large alterations to the genome of somatic cells with minimal reliance upon host DNA repair pathways, unlike nuclease-based gene editing technologies.
  • Permanently adding new DNA to dividing cells, unlike AAV-based gene therapy technologies.
  • Writing new DNA sequences into the genome by delivering only RNA.
  • Allowing repeated administration of treatments to patients in order to dose genetic medicines to effect, which is not possible with current gene therapies.

Tessera has licensed Flagship Pioneering’s intellectual property estate, which was begun in 2018 with seminal patent filings supporting both RNA and DNA Gene Writing technologies.

Tessera’s Scientific Advisory Board includes Luigi Naldini, David Schaffer, Andrew Scharenberg, Nancy Craig, George Church, Jonathan Weissman, and John Moran, who collectively have decades of experience in developing gene therapies and gene editing technologies, and also have commercial expertise from 4D, UniQure, Casebia, Cellectis, Magenta, and Editas. Tessera’s Board of Directors includes John Mendlein, Flagship Executive Partner and former CEO of multiple companies; Melissa Moore, Chair of Tessera’s Scientific Advisory Board, Chief Scientific Officer of Moderna, member of the National Academy of Sciences, and founding co-director of the RNA Therapeutics Institute; Geoffrey von Maltzahn; and Noubar Afeyan. The 30-person R&D team at Tessera has deep genetic medicine and startup expertise, including alumni from Editas, Intellia, Beam, Casebia, and Moderna.

About Tessera Therapeutics
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing™, a new biotechnology designed to offer scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing, while eliminating important limitations in their reach, utilization and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-class category companies to transform human health and sustainability.

About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $34 billion in aggregate value. To date, Flagship is backed by more than $4.4 billion of aggregate capital commitments, of which over $1.9 billion has been deployed toward the founding and growth of its pioneering companies alongside more than $10 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics, Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS). – Flagship Pioneering

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
We hardly made it before, but this summer something’s going on, our audience stats show bizarre patterns, we’re severely under estimates and the last savings are gone. We’re not your responsibility, but if you find enough benefits in this work…
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

You’ve likely heard of IG Farben, bud have you ever heard of American IG and the follow up story?

Imagine that the brutal experiments at Auschwitz were better concealed and the prisoners were drugged and brainwashed to believe that’s the best world out there for them. Then find out that the management has never stopped winning, expanding and perfecting their business model, up to today’s Great Reset.

This report is a video presentation

or CLICK HERE TO WATCH ON ODYSEE

good stuff that i had to leave out the video documentary:

Rockefellers brought the Nazi doctors and researchers to the US

SOURCE

ANSCO

Founded in Binghamton, New York, in 1901, Ansco was a manufacturer of photographic products and film. Ansco was originally founded through the merger of E. Anthony & Company and Scovill Manufacturing. In 1928, Ansco merged with Agfa to form Agfa-Ansco. The new corporation was a division of General Aniline and Film (GAF) Corporation, which was controlled by the German chemical cartel IG Farben. After Germany declared war on the United States in 1941, the United States Government seized the assets of GAF, including Agfa-Ansco. In 1943, the company removed “Agfa” from its name, once again becoming Ansco. The United States Justice Department oversaw Ansco’s operation until 1965, when government-held stock in GAF was sold to the public. In 1977, GAF eliminated its line of consumer photography products, including those manufactured by Ansco at the Binghamton facility. GAF also sold the Ansco trademark to Haking Enterprises. GAF continued to manufacture film at the Binghamton plant for industrial and medical use until 1981, when it sold the plant to Anitec Image Corporation. Over the next two decades, the former Ansco facility was sold several times, and in 2000, it was demolished.

Prior to the late 1970s, dozens of asbestos-containing materials were utilized in the construction and maintenance of buildings at Ansco’s Binghamton facility, including fireproof insulation, pipe covering and insulating cement. Inhaling dust from the application and removal of asbestos-containing materials placed workers at risk for developing an asbestos-related disease, such as mesothelioma or lung cancer.

Fireproof insulation was applied to structural steel during the construction of buildings at Ansco. Fireproofing materials were manufactured as a dry mixture of asbestos, linen and cement, packaged in fifty-pound paper bags. The dry mixture was mixed with water and sprayed onto the structural steel using a hose. Pouring, mixing and spraying fireproof insulation created clouds of asbestos-containing dust. After the fireproofing material was applied, it was typical for tradesmen, such as electricians or pipefitters, to scrape the fireproofing material from structural steel in order to install pipes and conduits. When the fireproof insulation was disturbed, asbestos fibers and dust became airborne.

Workers applied asbestos-containing pipe covering to pipes at the Binghamton Ansco facility. Pipe covering was applied to numerous piping systems in order to maintain stable internal temperatures and to protect pipes from damage. When pipe covering was applied, asbestos fibers were emitted. Insulating cement was also applied to pumps, valves and other equipment. It was manufactured as a powder and mixed with water to prepare it for application. Mixing insulating cement caused asbestos-containing dust to become airborne.

source:

What’s Bayer been up to lately?
We find out from their website:

The Bio Revolution is redefining innovation in the life sciences. How this might be a game changer.

The life sciences have made great advances in the past years. Biology, life sciences and the megatrend of digitization are growing closer together, enabling new inventions that impact our daily lives in a scope that we speak of a Bio Revolution. This revolution is reinforced by rapid increases in computing power and the emergence of new capabilities in AI, automation, and data analytics. These trends are further accelerating the pace of innovation and the potential for higher R&D productivity in the life sciences.

All this has led to new ways to understand and explore biology. The range of life forms on earth is incredibly complex and diverse. However, the methods to analyze them can be remarkably similar. Technologies and methods are transcending disciplinary boundaries even faster.

The implications across the life sciences can be enormous:

For human health, for example, a deeper understanding of the relationship between genetics and disease has led to the emergence of precision medicine, which can potentially be more effective than the one-size-fits-all therapies of the past. In the future, new technologies could help the healthcare industry not only treat, but cure or even prevent diseases. New gene and cell therapies, for example, aim to cure genetic diseases, potentially enabling sustainable organ replacement or reversing autoimmune diseases.

The Bio Revolution has the potential to help address some of the most critical global challenges, from climate change to pandemics, chronic diseases, and worldwide food security. Experts estimate that a significant portion of the economic impact of biological applications will be in health care, agriculture, and consumer products.3 Already today, the Bio Revolution with its convergence of science and technology has created an explosion of research projects in science and business. Each year, the amount of Intellectual Property related to the Bio Revolution is increasing.4 This can be seen, for example, by the number of patents in CrispR or plant biotech. In short: the revolution is gaining momentum and holds a great promise for health and food alike.

Total number of CRISPR patent applications worldwide per year from 1984 to 2018.

Quote symbolFueled by digitalization, growing connectivity, and falling costs, important advances in biotechnology are intertwined with more systemic shift in how bio-innovation is undertaken and who is involved. Microbiome technologies, advanced genomics, gene editing and synthetic biology are among key enabling technologies that have the potential to change the face of bio-innovation. This broader redefinition of bio-innovation creates new prospects to help address important nutrition, environmental and development needs.

World Economic Forum, Bio-Innovation Dialogue Initiative

.At the Forefront of the Bio Revolution

As a leading life science company, Bayer is aligned with the long-term market trends in health and nutrition and offers innovative and sustainable solutions to tackle some of the key challenges for humanity. Bayer brings to the table an extensive knowledge of human and plant science, supported by its expertise in regulatory processes and an impressive global footprint to ultimately bring innovations from labs to market. https://www.youtube-nocookie.com/embed/EYE1gya7XiM?autoplay=1&start=0&rel=0

The Bio Revolution marks the beginning of a new era: Innovations enabled by the convergence of biology and technology have the potential to significantly improve our lives, our nutrition, and our health.

Did you know that Bayer is at the forefront of the wave of innovation coming from the Bio Revolution?

The Bio Revolution is expected to transform healthcare and agriculture over the next decades – but the revolution is already happening now. With its newly established cell and gene therapy platform in Pharmaceuticals and innovative gene-editing tools such as CRISPR, Bayer operates at the core of the Bio Revolution and has tremendous opportunities to improve health and nutrition.

In Pharma, Bayer’s new Cell & Gene Therapy (CGT) platform steers our strategy in the area and orchestrates our activities along the value chain providing an innovation ecosystem for the companies – including BlueRock Therapeutics and Asklepios BioPharmaceutical (AskBio), which are fully owned by Bayer but operate autonomously. These therapies hold the potential to significantly impact patients’ lives by moving from treating symptoms to potentially curative approaches.

Bayer’s development portfolio of cell and gene therapies already comprises eight advanced assets in different stages of clinical development. These are applicable in multiple therapeutic areas with high unmet need, such as neurodegenerative, neuromuscular and cardiovascular indications, with programs in Pompe disease, Parkinson’s disease, hemophilia A, and congestive heart failure. With over 15 preclinical assets in the cell and gene therapy field, the pipeline is expected to grow steadily year by year.

Yet Bayer is not only using biotechnology to advance health – the promise for agriculture is just as inspiring. In the Crop Science Division, for example, tools like CRISPR can make changes to plant DNA with more precision than ever before and make plants more weather- or disease-resistant, enabling farmers to grow more or better-quality products under changing conditions.

Advancing genetic solutions for a sustainable future (1)PreviousNext

Did you know that Leaps by Bayer invests into potentially disruptive technologies to tackle some of the largest, unsolved challenges in the life sciences?

With Leaps by Bayer – our impact investment approach utilizing venture capital – we are constantly scanning for additional potential breakthroughs that hold promise to either cure or treat people from diseases or help feed a growing population with less impact on the environment.

$1 Billion

Since 2015, Leaps by Bayer has invested over $1 billion in ventures that tackle fundamental breakthroughs and shift core paradigms in our industries.

Leaps by Bayer has an investment focus on potentially disruptive solutions in the fields of healthcare and agriculture. The Leaps investment approach is remarkable: It aims to invest into or build up new innovative companies. Bayer supports those companies by enabling the exchange of proprietary assets, which can include sharing own patents or providing access to the Bayer network’s technical capabilities and 150 years of expertise. The companies remain autonomous with respect to decision making, while Leaps facilitates and supports them in a so-called active incubation process. Experienced team members actively engage in the young companies’ development by providing resources and helping them to steer the initial strategic direction. Today, the investment portfolio includes more than 35 companies advancing potential breakthrough technologies.

Quote symbolLeaps is our way of thinking big.

Werner Baumann, CEO of Bayer AG

Many Leaps ventures have made significant progress towards unlocking the potential of new technology platforms with a promising and transformative potential. BlueRock Therapeutics, for example, started as a Leaps investment and is now an integral part of Bayer’s CGT platform and just received clearance to proceed with a phase I trial in Parkinson’s disease.

Other companies, like the biopharmaceutical player Triumvira, are specialized on next generation immuno-oncology treatments. Triumvira focuses on novel T-cell therapies that aim to be safer and more efficacious than current cell therapy cancer treatments. Treating, curing and preventing cancer is one of the focus areas of Leaps by Bayer, since this group of diseases still represents one of today’s biggest health challenges with limited curative or preventative therapies available.

Quote symbolWe face a huge disease burden, and the way we produce food isn’t sustainable for the planet. I believe the Bio Revolution can help us overcome these issues.

Jürgen Eckhardt, Head of Leaps by Bayer

Leaps is also investing in the development of sustainable biotechnological solutions in the field of agriculture. One of the ventures in this field is Joyn Bio, a company that aims to significantly reduce the environmental impact of synthetic nitrogen fertilizers through a technology that fixes nitrogen into the soil. Nitrogen is one of the most important nutrients essential for every plant to grow, however, its use and production as a fertilizer is estimated to contribute 3-5% to all global greenhouse gas emissions. Joyn Bio is working on an engineered microbe that enables cereal crops like corn, wheat, and rice to convert nitrogen from the air into a form they can use to grow. This technology may have the potential to help farmers use nitrogen in new ways, and as a result, reduce agriculture’s environmental footprint.

Leaps portfolio

The Leaps by Bayer investment portfolio includes more than 35 companies.

At least that’s what Bayer says. All I know is that they’re still running the show.

Ex-Standard Oil

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
We hardly made it before, but this summer something’s going on, our audience stats show bizarre patterns, we’re severely under estimates and the last savings are gone. We’re not your responsibility, but if you find enough benefits in this work…
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

We gave up on our profit shares from masks, if you want to help us, please use the donation button!
We think frequent mask use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness.
Get it here!